Back to results
US 2025/0375467 A1Published application
Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same
AssigneeAstellas US LLC
InventorsGary COOK, Pravin DUGEL, Tatu ASSMUTH
Life of this patent
Estimating the term…
Abstract
Some embodiments relate to a sustained release silica hydrogel composite comprising an anti-complement agent and methods of using same to treat ophthalmological conditions. The anti-complement agent may be an anti-C5 agent comprising a C5-specific aptamer.
Claims27
A sustained release silica hydrogel composite, the composite comprising:
- silica content in the range of 5-35% and anti-C5 agent in the range of 1-40%, wherein the anti-C5 agent comprises a C5-specific aptamer, in which the aptamer comprises a nucleotide sequence of fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCf CfUmGfCmG-3T (SEQ ID NO:
- 1), in which fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine.
A formulation comprising a population of microparticles, the microparticles comprising:
- silica content in the range of 10-70% and anti-C5 agent in the range of 5-50%, wherein the anti-C5 agent comprises a C5-specific aptamer, in which the aptamer comprises a nucleotide sequence of fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCf CfUmGfCmG-3T (SEQ ID NO:
- 1), in which fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine.
Dependencies are inferred from the claim text.